Defining Predictors of RT Response to Vedolizumab in IBD

  • End date
    Jun 17, 2024
  • participants needed
  • sponsor
    Washington University School of Medicine
Updated on 7 October 2022


The overall goal of the study is to develop data that can convincingly guide clinicians on the use and efficacy of vedolizumab in patients with small bowel CD. There is an unmet need to identify response to vedolizumab in small bowel CD using objective endpoints. Current data suggest that MR enterography may meet this unmet need. There is an additional unmet need to develop predictive models incorporating both clinical and baseline radiological and endoscopic variables with higher discriminatory performance in identifying longer term clinical remission with vedolizumab. Finally, this proposal is strengthened by the exploratory studies which may identify new proteomic biomarkers that correlate with longer term radiological response with vedolizumab reflecting its latency of response. If successful, these serum biomarkers may guide a personalized approach to the treatment of small bowel CD with vedolizumab, allowing early identification of PNR, monitoring disease activity and the pharmacodynamics of vedolizumab.

Condition Crohn Disease of Small Intestine
Treatment Vedolizumab 300 MG Injection [Entyvio]
Clinical Study IdentifierNCT03142321
SponsorWashington University School of Medicine
Last Modified on7 October 2022


Yes No Not Sure

Inclusion Criteria

Moderate to severe disease activity small bowel CD (small bowel only or ileocecal only) visible on MRE
Initiated on Vedolizumab with/without thiopurines or methotrexate
≥18 years old

Exclusion Criteria

Age <18
Planned surgery prior to the first follow-up MRE
Inability to provide informed consent
Perianal CD will be excluded since assessment requires performance of additional MRI of the pelvis
Individuals with colonic involvement other than involvement of the ascending colon and cecum
Inpatient scans will only be included if this is a MRE and adequate small bowel distension with appropriate contrast has been achieved
If unable to provide informed consent
Contraindications for MRE including chronic kidney disease that precludes contrast administration, implanted medical devices that are contraindicated for MRE
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note